- Statistical techniques to construct assays for identifying likely responders to a treatment under evaluation from cell line genomic dataErich P Huang
Biometric Research Branch Department of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health Rockville, MD 20852, USA
BMC Cancer 10:586. 2010..In this manuscript, we present a novel approach to developing robust genomic predictors that are not only capable of generalizing from in-vitro to patient, but are also amenable to clinically validated assays such as qRT-PCR...
- Effect of FCGR2A and FCGR3A variants on CLL outcomeDavid Dornan
Molecular Diagnostics and Cancer Cell Biology, Genentech Inc, South San Francisco, CA, USA
Blood 116:4212-22. 2010..42 CI]; P = .48, respectively). Overall, our results suggest that FCGR2A and FCGR3A polymorphisms do not significantly influence the outcomes of relapsed or refractory CLL patients treated with FC or the monoclonal antibody regimen R-FC...